Skip to main content

Table 2 Prognostic significance of clinicopathologic factors and influence on long-term recurrence/metastasis-free survival in entire cohort and MBC subset

From: Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified

Covariates

Univariate analysis

Multivariate analysis cox regression of survival

MBC

Entire cohort

MBC

Entire cohort

 

Χ 2

P

Χ 2

P

RR (95% CI)

P

RR (95% CI)

P

Age ≤50 years

<0.001

0.998

0.47

0.490

1.32 (0.38 to 4.56)

0.666

1.39 (0.91 to 2.12)

0.129

Tumor size ≥2 cm

0.62

0.432

25.35

<0.001

0.42 (0.08 to 2.31)

0.320

2.71 (1.39 to 5.28)

0.003

Node-positive

2.34

0.127

99.36

<0.001

0.74 (0.16 to 3.53)

0.710

2.40 (1.42 to 4.07)

0.001

Higher TNM stage

4.53

0.031

95.60

<0.001

7.84 (0.76 to 80.54)

0.083

2.19 (1.33 to 3.62)

0.002

ER-positive

0.14

0.706

0.57

0.184

1.15 (0.34 to 3.98)

0.817

0.92 (0.58 to 1.44)

0.697

PR-positive

0.04

0.847

0.38

0.103

1.06 (0.28 to 3.92)

0.936

0.80 (0.52 to 1.24)

0.321

HER2/neu-positive

1.70

0.193

8.29

0.004

1.31 (0.37 to 4.69)

0.677

1.31 (0.86 to 2.00)

0.204

Chemotherapy

1.02

0.314

0.89

0.345

0.37 (0.07 to 2.01)

0.251

0.60 (0.30 to 1.20)

0.151

Radiotherapy

7.75

0.005

96.42

<0.001

0.13 (0.03 to 0.71)

0.015

1.81 (1.22 to 2.92)

0.015

Hormonotherapy

0.13

0.722

18.70

<0.001

0.50 (0.13 to 1.93)

0.317

0.69 (0.43 to 1.01)

0.122

  1. CI, confidence interval; ER, estrogen receptor; HER2/neu, human epidermal growth factor receptor 2; MBC, medullary breast carcinoma; PR, progesterone receptor; RR, relative risk.